Humana · Cftr Trikafta · US health-plan appeal rights

Cftr Trikafta denied as not FDA-approved for this use by Humana?

Q: How long do I have to appeal a Humana Cftr Trikafta denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Medicare Advantage Part D specialty tier

The Humana angle on Cftr Trikafta

## Why Humana May Issue a "Not FDA-Approved" Denial for Trikafta

Trikafta (elexacaftor/tezacaftor/ivacaftor) has full FDA approval for cystic fibrosis patients who carry at least one eligible CFTR mutation. A "not FDA-approved" denial from Humana almost always reflects one of three scenarios: (1) the plan's system could not verify that your documented mutation falls within the current approved indication, (2) the request was flagged as off-label because of a mutation or patient profile that falls outside the current label, or (3) an administrative coding error in the prior-authorization submission. Each scenario has a distinct appeal path.

## Why It Is Appealable

For on-label use, FDA approval is a matter of public record and the denial is factually incorrect. Supply the current FDA-approved prescribing label and your certified genotype report, and the basis for the denial disappears. For potential off-label use, the appeal requires published clinical literature and a detailed medical-necessity argument, but the right to appeal the determination remains the same.

## Federal Appeal Framework

Internal appeal (Level 1): File within the deadline on your EOB. Humana must respond within 30 days (pre-service, non-urgent) or 72 hours (urgent/expedited). Cystic fibrosis is a progressive disease; most prescribers can document urgency to support the expedited track.
External review (ACA §2719 / ERISA §503): After internal remedies are exhausted, you have approximately 4 months from the denial notice to request an IRO review. External reviewers apply objective clinical evidence independent of Humana's internal policy. You may also request expedited external review when health is immediately at risk.

## Documentation to Gather

1. Current FDA-approved prescribing label — download from FDA.gov; print the approved indication section and confirm your mutation is listed. 2. Certified CFTR genotype report — from a CLIA-certified laboratory; confirms your mutation by name and class. 3. CF specialist medical-necessity letter — your prescriber should cite the FDA label's approved indication, confirm that your genotype falls within it, and state that this is an on-label use of the drug. 4. Denial letter and EOB — include the exact language Humana used so the appeal directly addresses the stated basis. 5. Humana's experimental/investigational or coverage policy for Trikafta — request from Humana in writing; review whether it contains any language about mutation verification requirements.

## Criteria-Mapping Structure

| Humana Denial Basis | Your Counter-Evidence | |---|---| | FDA approval status disputed | Current FDA label from FDA.gov (attach full label or indication section) | | Mutation not confirmed within indication | Certified lab report confirming mutation name, [lab], [date] | | Off-label use alleged | Prescriber letter confirming on-label use; or, if off-label, published literature + necessity letter |

## Practical Tip

If the denial letter cites a specific mutation or approval date that appears incorrect, call Humana's clinical review line before filing the written appeal. A phone call to the reviewing pharmacist or physician reviewer can sometimes resolve a factual error in the system without requiring a formal appeal cycle.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other insurers on Cftr Trikafta

Other denial reasons for Humana Cftr Trikafta

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.